'Risk minimisation' presentation slideshows

RMP: DEFINITIONS AND REGULATORY ASPECTS

RMP: DEFINITIONS AND REGULATORY ASPECTS. Marc Czarka, MD, FBCPM Managing Partner HM3A ( Market Autorisation and Access Associates ). IS IT A NEW ITCH?. Nature 296, 387 - 390 ( 01 April 1982 ); doi:10.1038/296387a0

332 views • 22 slides

Leading schools in changing times

Leading schools in changing times. Ola Hoff Kaldestad 2009. Schools are complicated institutions. Peter Senge : Schools that learn (2000). Systems Thinking. The Knowledge promotion Reform 2006. In order to climb the PISA ladder. FOUR PILLARS OF EDUCATION (UNESCO, 1996).

532 views • 20 slides

258 views • 16 slides

CTD, Safety

CTD, Safety. Tanja Braakman Genzyme Europe BV Pharmacovigilance Department. CTD, Safety. 2.7.4 Summary of Clinical Safety 1.x EU-RMP. 2.7.4 Summary of Clinical Safety. Summary of data relevant to safety in the intended patient population; integration of individual CSRs or other reports.

339 views • 16 slides

165 views • 16 slides

The New( ish ) European Pharmacovigilance Legislation

The New( ish ) European Pharmacovigilance Legislation. Jacquelyn Awigena-Cook Associate Director, Head PV Policy. Disclaimer. The New European Pharmacovigilance Legislation.

463 views • 11 slides